TITLE

Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine

AUTHOR(S)
Beck, Bernhard R.; Hatz, Christoph; Brönnimann, Rainer; Herzog, Christian
PUB. DATE
November 2003
SOURCE
Clinical Infectious Diseases;11/1/2003, Vol. 37 Issue 9, p126
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This study demonstrates that a booster dose of the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal (Berna Biotech) is highly immunogenic in subjects who received a single primary dose of this vaccine 18–54 months earlier. There were no significant differences in geometric mean antibody titers (GMTs) among subjects who received the booster dose 18–29 months (GMT, 2330 mIU/mL), 30–41 months (GMT, 2395 mIU/mL), or 42–54 months (GMT, 2432 mIU/mL) after primary vaccination, indicating that delays in the administration of booster vaccination do not lead to a loss of immunogenicity.
ACCESSION #
11489938

 

Related Articles

  • Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Yun-Mi Song; Joohon Sung; Soonha Yang; Yon Ho Choe; Yun Sil Chang; Won Soon Park // European Journal of Pediatrics;Aug2007, Vol. 166 Issue 8, p813 

    In spite of adequate immunoprophylaxis, perinatal transmission of hepatitis B virus (HBV) has not been completely eliminated. This study evaluated the factors associated with the failure of HBV immunoprophylaxis. The study participants were 144 children who were born to HBsAg-seropositive...

  • Hepatitis A and B Booster Recommendations: Implications for Travelers. Zuckerman, Jane N.; Connor, Bradley A.; Von Sonnenburg, Frank // Clinical Infectious Diseases;10/1/2005, Vol. 41 Issue 7, p1020 

    Hepatitis A and B are serious vaccine-preventable diseases with a predominantly overlapping epidemiological distribution. Travelers, a term encompassing a range of individuals, are at risk of contracting these diseases if they are unvaccinated. Although the benefits of the primary vaccination...

  • Travel Immunizations. Lo Re III, Vincent; Gluckman, Stephen J. // American Family Physician;7/1/2004, Vol. 70 Issue 1, p89 

    Advising travelers on vaccine-preventable illnesses is increasingly becoming the responsibility of primary care physicians. The approach to vaccine recommendations should be based on a thorough assessment of the risks for travel-related diseases, the time available before and current knowledge...

  • Factors influencing hepatitis B vaccine uptake in injecting drug users. McGregor, J.; Marks, P. J.; Hayward, A.; Bell, Y.; Slack, R. C. B. // Journal of Public Health Medicine;Jun2003, Vol. 25 Issue 2, p165 

    Background Hepatitis B infection in injecting drug users is an important public health problem. Active immunization against hepatitis B is immunogenic and safe, but uptake rates in targeted vaccination programmes are low. This study was undertaken to identify factors associated with the uptake...

  • The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule. Chatterjee, Sukanta; Rego, Sylvan J.; D'Souza, Fulton; Bhatia, B. D.; Collard, Alix; Datta, Sanjoy K.; Jacquet, Jeanne-Marie // BMC Infectious Diseases;2010, Vol. 10 Issue 1, p298 

    Background: Combination vaccines improve coverage, compliance and effectively introduce new antigens to mass vaccination programmes. This was a phase III, observer-blind, randomized study of GSK Biologicals diphtheriatetanus- whole cell pertussis vaccine combined with hepatitis B and Haemophilus...

  • Parents back universal hep B jabs. Baines, Emma // GP: General Practitioner;3/18/2005, p14 

    The article informs that universal vaccination for hepatitis B could be introduced across the UK. Hepatitis B vaccination is restricted to high-risk populations in the UK, even though the WHO recommends universal hepatitis B vaccination of infants or adolescents. One reason given for this policy...

  • New genetic associations detected in a host response study to hepatitis B vaccine. Davila, S.; Froeling, F. E. M.; Tan, A.; Bonnard, C.; Boland, G. J.; Snippe, H.; Hibberd, M. L.; Seielstad, M. // Genes & Immunity;Apr2010, Vol. 11 Issue 3, p232 

    The immune response to hepatitis B vaccination differs greatly among individuals, with 5–10% of healthy people failing to produce protective levels of antibodies. Several factors have been implicated in determining this response, chiefly individual genetic variation and age. Aiming to...

  • Research brief: Two-dose hepatitis B schedule favoured.  // GP: General Practitioner;11/5/2004, p11 

    The article presents information on Scottish researchers who had investigated determinants of hepatitis B vaccine (HBV) uptake among some 10,800 school-based adolescents. Those from the most deprived areas were 44 and 53 per cent less likely to receive two and three doses of HBV, respectively,...

  • Can Specific Heterologous Immunity Boost Hepatitis B Vaccine Responses? Diepolder, Helmut M. // Journal of Infectious Diseases;8/1/2008, Vol. 198 Issue 3, p297 

    The article discusses the effect of a specific heterologous immunity in boosting Hepatitis B Vaccinne responses. The currently licensed hepatitis B vaccines are highly effective and induce protective antibody titers in 95% of vaccines after three immunizations. Moreover, immunogenicity of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics